The real reason cannabis approval is so slow is because Big Pharma wants to patent it
The fact that Big Pharma has been a driving force behind marijuana prohibition is hard to ignore — especially when it comes to the number of opioid manufacturers that have spent thousands of dollars fighting against medical marijuana. The plague of opioid addiction has struck the United States hard, leaving countless numbers of overdoses, deaths and destroyed families in its wake. And yet, the people who pushed these highly addictive drugs onto the unsuspecting public are suddenly playing martyr, spending nearly a billion dollars to keep opioids on the market and fight cannabis legalization, under the alleged pretense of public safety. It just doesn’t add up, does it?
Studies have shown that medical cannabis can help reduce opioid abuse and save lives, but to Big Pharma, profits are always more important than people. Indeed, if the pharmaceutical industry was actually concerned about human health, as they proclaim to be, lobbying and bribing politicians wouldn’t be at the top of their agenda. As Allen Frances, Professor Emeritus at Duke University, contends, “Recent history makes clear that Pharma owns Washington and also many state capitals. It invests twice as much on marketing and lobbying as it does on research and is much better at buying politicians than producing better products.”